Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat.

Satoru MitsuboshiTakahiro NiimuraMasaya KandaShunsuke IshidaYoshito ZamamiKeisuke Ishizawa

Published in: The Annals of pharmacotherapy (2021)

Our findings suggest that patients being treated with intravenous MTX who concomitantly use febuxostat may be at an increased risk of hematologic events, presumably due to BCRP-mediated drug-drug interaction.

Keyphrases

end stage renal disease
newly diagnosed
high dose
ejection fraction
chronic kidney disease
prognostic factors
emergency department
low dose
young adults
protein protein
amino acid
electronic health record